Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ascelia Pharma AB ( (SE:ACE) ) has provided an announcement.
Ascelia Pharma AB’s annual general meeting on 4 May 2026 approved the 2025 accounts and decided to carry forward SEK 13.4 million without paying a dividend, while granting discharge from liability to the board and CEO. Shareholders re-elected the existing board, confirmed Peter Benson as chairman, set board and committee remuneration structures including synthetic share-based fees, and reappointed Öhrlings PricewaterhouseCoopers AB with Mikael Nilsson as auditor in charge.
The meeting adopted new guidelines for senior executive pay and approved the 2025 remuneration report, but rejected a proposed authorization for the board to issue new shares, prompting the board to seek further input from major shareholders and plan a revised proposal. Investors also backed a new long-term performance-based share saving program for employees, authorizing related C-share issuances and buybacks that could dilute existing ordinary shares by about 3.67%, underscoring Ascelia’s focus on equity-based incentives while signaling shareholder caution on broader capital-raising mandates.
More about Ascelia Pharma AB
Ascelia Pharma AB is a Swedish pharmaceutical company based in Malmö, focused on developing specialty oncology treatments and related pharmaceutical products. The company targets niche indications where there is a clear unmet medical need, positioning itself within the broader life sciences and healthcare sector.
YTD Price Performance: -6.69%
Average Trading Volume: 702,579
Technical Sentiment Signal: Sell
Current Market Cap: SEK380.6M
See more insights into ACE stock on TipRanks’ Stock Analysis page.